CR8193A - Piperazina con o sustituida de grupos feniles y su uso como inhibidores de glyt 1 - Google Patents

Piperazina con o sustituida de grupos feniles y su uso como inhibidores de glyt 1

Info

Publication number
CR8193A
CR8193A CR8193A CR8193A CR8193A CR 8193 A CR8193 A CR 8193A CR 8193 A CR8193 A CR 8193A CR 8193 A CR8193 A CR 8193A CR 8193 A CR8193 A CR 8193A
Authority
CR
Costa Rica
Prior art keywords
fenile
piperazina
glyt
inhibitors
replaced
Prior art date
Application number
CR8193A
Other languages
English (en)
Inventor
Jolidon Synese
Narquizian Robert
Heinrich Nettekoven Matthias
David Norcross Roger
Pinard Emmanuel
Stalder Henri
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34130061&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR8193(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR8193A publication Critical patent/CR8193A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)

Abstract

La invencion se refiere a compuestos de formula en donde los sustituyentes se describen en la reivindicacion 1.
CR8193A 2003-08-11 2006-01-17 Piperazina con o sustituida de grupos feniles y su uso como inhibidores de glyt 1 CR8193A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03017614 2003-08-11

Publications (1)

Publication Number Publication Date
CR8193A true CR8193A (es) 2006-10-06

Family

ID=34130061

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8193A CR8193A (es) 2003-08-11 2006-01-17 Piperazina con o sustituida de grupos feniles y su uso como inhibidores de glyt 1

Country Status (36)

Country Link
US (2) US7319099B2 (es)
EP (1) EP1656361B1 (es)
JP (1) JP4252598B2 (es)
KR (1) KR100774622B1 (es)
CN (1) CN1867554B (es)
AR (1) AR045360A1 (es)
AT (1) ATE382611T1 (es)
AU (1) AU2004263306B2 (es)
BR (1) BRPI0413497B8 (es)
CA (1) CA2534675C (es)
CO (1) CO5650253A2 (es)
CR (1) CR8193A (es)
CY (1) CY1108616T1 (es)
DE (1) DE602004011076T2 (es)
DK (1) DK1656361T3 (es)
EA (1) EA009986B1 (es)
EC (1) ECSP066358A (es)
EG (1) EG26404A (es)
ES (1) ES2297458T3 (es)
HR (1) HRP20080137T3 (es)
IL (1) IL173274A (es)
MA (1) MA27995A1 (es)
ME (1) ME00116B (es)
MX (1) MXPA06001665A (es)
MY (1) MY145356A (es)
NO (1) NO332263B1 (es)
NZ (1) NZ544820A (es)
PL (1) PL1656361T3 (es)
PT (1) PT1656361E (es)
RS (2) RS20060076A (es)
SI (1) SI1656361T1 (es)
TN (1) TNSN06042A1 (es)
TW (1) TWI289556B (es)
UA (1) UA85194C2 (es)
WO (1) WO2005014563A1 (es)
ZA (1) ZA200601146B (es)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050119251A1 (en) * 2001-12-21 2005-06-02 Jian-Min Fu Nicotinamide derivatives and their use as therapeutic agents
AU2004263306B2 (en) 2003-08-11 2010-04-22 F. Hoffmann-La Roche Ag Piperazine with or-substituted phenyl group and their use as GLYT1 inhibitors
JP4563387B2 (ja) * 2003-09-09 2010-10-13 エフ．ホフマン−ラ ロシュ アーゲー 精神病の処置のためのグリシン取り込み阻害剤としての１−ベンゾイル−ピペラジン誘導体
DK1663232T3 (da) * 2003-09-09 2008-02-04 Hoffmann La Roche Benzimidazolderivater som human chymase-inhibitorer
MX2007003327A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos, y su uso como mediadores de estearoil-coa desaturasa.
WO2006034341A2 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
BRPI0515482A (pt) 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc derivados heterocìclicos e seus usos como agentes terapêuticos
US8071603B2 (en) 2004-09-20 2011-12-06 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
TW200626138A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
CA2580855A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
JP4958787B2 (ja) * 2004-09-20 2012-06-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヒトステアロイル−ＣｏＡデサチュラーゼを阻害するためのピリジン誘導体
AR051026A1 (es) 2004-09-20 2006-12-13 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
MX2007003329A (es) * 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y biciclicos y su uso como inhibidores de estearoil-coa-desaturasa (scd).
KR100880093B1 (ko) * 2004-12-09 2009-01-23 에프. 호프만-라 로슈 아게 페닐-피페라진 메탄온 유도체
CA2590316A1 (en) * 2004-12-15 2006-06-22 F. Hoffmann-La Roche Ag Bi- and tricyclic substituted phenyl methanones as glycine transporter i (glyt-1) inhibitors for the treatment of alzheimer's disease
US7485637B2 (en) * 2005-01-04 2009-02-03 Hoffmann-La Roche Inc. Benzoyl-tetrahydropiperidine derivatives
KR20070094955A (ko) * 2005-01-06 2007-09-27 에프. 호프만-라 로슈 아게 신경 질환 및 신경정신 질환을 치료하기 위한 글라이신수송자 1(ｇｌｙｔ-1) 저해제로서의 설파닐 치환 페닐메타논
RU2396270C2 (ru) 2005-01-07 2010-08-10 Ф.Хоффманн-Ля Рош Аг Производные [4-(гетероарил)пиперазин-1-ил]-(2,5-замещенный фенил)метанона в качестве ингибиторов переносчика глицина-1 (glyt-1) для лечения неврологических и психоневрологических заболеваний
JP2008527016A (ja) * 2005-01-18 2008-07-24 エフ．ホフマン−ラ ロシュ アーゲー 神経及び神経精神病の疾患の治療のためのグリシントランスポーター１（ＧｌｙＴ−１）阻害剤としての２，５−二置換フェニルメタノン誘導体
ES2332529T3 (es) * 2005-01-26 2010-02-08 F. Hoffmann-La Roche Ag Derivados de fenil-metanona y su empleo como inhibidores del transportador 1 de glicina.
CN101119968B (zh) * 2005-02-07 2011-08-31 弗·哈夫曼-拉罗切有限公司 作为甘氨酸转运蛋白1抑制剂的杂环取代的苯基甲酮衍生物
GB0505085D0 (en) * 2005-03-11 2005-04-20 Glaxo Group Ltd Compounds
GB0505086D0 (en) * 2005-03-11 2005-04-20 Glaxo Group Ltd Compounds
GB0505084D0 (en) * 2005-03-11 2005-04-20 Glaxo Group Ltd Compounds
US8541457B2 (en) 2005-06-03 2013-09-24 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors
JP4219976B2 (ja) * 2005-07-08 2009-02-04 エフ．ホフマン−ラ ロシュ アーゲー １，１，１−トリフルオロアセトンの不斉還元
GB0523853D0 (en) * 2005-11-24 2006-01-04 3M Innovative Properties Co Fluorinated surfactants for use in making a fluoropolymer
WO2007078335A2 (en) * 2005-12-21 2007-07-12 Decode Genetics, Ehf. Biaryl nitrogen heterocycle inhibitors of lta4h for treating inflammation
CA2651700A1 (en) * 2006-05-22 2007-11-29 Merck Frosst Canada Ltd. Cyclic amine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
ES2406085T3 (es) 2006-06-22 2013-06-05 F. Hoffmann-La Roche Ag Derivados de fenil-metanona sustituida y su empleo como inhibidores de receptores de GlyT1 y GlyT2
DK2041088T3 (da) 2006-06-28 2014-04-07 Amgen Inc Glycintransporter-1 inhibitorer
CA2658773C (en) 2006-07-27 2014-04-08 F. Hoffmann-La Roche Ag Asymmetric hydrogenation of 1,1,1-trifluoroacetone
JP5162598B2 (ja) * 2006-11-30 2013-03-13 ダウ アグロサイエンシィズ エルエルシー ２−置換−５−（１−アルキルチオ）アルキルピリミジンの製造方法
HRP20150573T1 (xx) * 2006-12-28 2015-07-03 F. Hoffmann - La Roche Ag KO-KRISTALNI OBLIK „A“ METILPARABENA OD [4-(3-FLUORO-5-TRIFLUOROMETIL-PIRIDIN-2-IL)-PIPERAZIN-1-IL]-[5-METANSULFONIL-2-((S)-2,2,2-TRIFLUORO-1-METIL-ETOKSI)-FENIL]-METANONA
JP4745446B2 (ja) 2007-03-05 2011-08-10 エフ．ホフマン−ラ ロシュ アーゲー Ｇｌｙｔ−１阻害剤の合成
AU2008258487B2 (en) * 2007-06-08 2012-11-15 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
JO2972B1 (en) * 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine / piperazine derivatives
EP2152271B1 (en) * 2007-06-08 2015-10-21 Janssen Pharmaceutica, N.V. Piperidine/piperazine derivatives
CA2687918C (en) * 2007-06-08 2016-11-08 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
US8420670B2 (en) 2007-08-22 2013-04-16 Abbott Laboratories 4-benzylaminoquinolines, pharmaceutical compositions containing them, and their use in therapy
MX2010010773A (es) 2008-04-01 2011-04-11 Abbott Gmbh & Co Kg Tetrahidroisoquinolinas, composiciones farmaceuticas que las contienen y su uso en terapia.
JP5579170B2 (ja) * 2008-06-05 2014-08-27 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｄｇａｔ阻害剤とｐｐａｒ作動薬を含有する薬剤組み合わせ物
WO2010025375A1 (en) * 2008-08-29 2010-03-04 Treventis Corporation Compositions and methods of treating amyloid disease
US20160283652A1 (en) 2008-08-29 2016-09-29 Treventis Corporation Methods for identifying inhibitors of amyloid protein aggregation
PE20110434A1 (es) 2008-11-04 2011-07-01 Hoffmann La Roche Compuestos radiomarcados derivados de [5-metanosulfonil-fenil]-[5-(tetrahidro-piran-4-il)-1,3-dihidro-isoindol-2-il]-metanona
CN101759665B (zh) * 2008-12-23 2012-03-28 江苏恩华药业股份有限公司 取代苯基哌嗪芳烷醇衍生物及其在制备镇痛药物中的应用
AR075442A1 (es) 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia
TW201038569A (en) 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
WO2011002067A1 (ja) * 2009-07-02 2011-01-06 武田薬品工業株式会社 複素環化合物およびその用途
US20120035156A1 (en) * 2010-08-09 2012-02-09 Daniela Alberati Combination of glyt1 compound with antipsychotics
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8609672B2 (en) 2010-08-27 2013-12-17 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8853196B2 (en) 2011-08-05 2014-10-07 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
MX2014006004A (es) 2011-11-18 2015-04-16 Abbvie Deutschland Derivados de aminobenzociclohepteno, aminotetralina, aminoindano y fenalcilamina n-sustituidas, composiciones farmaceuticas que los contienen, y su uso en terapia.
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2014163156A1 (ja) * 2013-04-04 2014-10-09 味の素株式会社 脱保護方法
WO2014192865A1 (ja) * 2013-05-30 2014-12-04 大日本住友製薬株式会社 フェニルピペラジン誘導体
KR101472916B1 (ko) 2013-06-27 2014-12-16 한국과학기술연구원 모르폴린 또는 피페라진 화합물, 및 도네페질을 포함하는 인지 장애 관련 질병의 예방 또는 치료용 약학적 조성물
MX2016004934A (es) 2013-10-17 2016-12-20 Abbvie Deutschland Derivados de aminotetralina y aminoindano, composiciones farmaceuticas que los contienen, y su uso en terapia.
EP3057960B1 (en) 2013-10-17 2019-02-27 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
CN104628679B (zh) * 2013-11-08 2018-02-09 江苏恩华药业股份有限公司 Bitopertin的合成方法及其中间体
EP3076953A1 (en) * 2013-12-03 2016-10-12 F. Hoffmann-La Roche AG Pharmaceutical composition
RU2577039C2 (ru) * 2014-02-28 2016-03-10 Закрытое Акционерное Общество "Вертекс" Вещество, обладающее сочетанной антиагрегантной, антикоагулянтной и вазодилаторной активностью, и способ получения n, n'-замещенных пиперазинов
EP3134406A1 (en) 2014-04-24 2017-03-01 Dart Neuroscience (Cayman) Ltd Substituted 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole and 4,5,6,7-tetrahydro-2h-pyrazolo [4,3-c]pyridine compounds as glyt1 inhibitors
MY189930A (en) * 2014-04-30 2022-03-22 Hoffmann La Roche Glyt1 inhibitors for use in the treatment of hematological disorders
US9550754B2 (en) 2014-09-11 2017-01-24 AbbVie Deutschland GmbH & Co. KG 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy
EP3215500A1 (en) 2014-11-05 2017-09-13 Dart NeuroScience (Cayman) Ltd. Substituted azetidinyl compounds as glyt1 inhibitors
CN105712952B (zh) * 2014-12-22 2021-03-26 上海翰森生物医药科技有限公司 2-取代氧基-5-甲砜基苯基哌嗪酰胺类似物及其制备方法和用途
CN105017098A (zh) * 2015-07-17 2015-11-04 大连奇凯医药科技有限公司 烷氧基类苯磺酰胺及其衍生物的制备工艺
CN106397312B (zh) * 2015-07-31 2020-03-24 广东东阳光药业有限公司 一种制备glyt-1抑制剂的方法
IL279152B2 (en) 2018-06-05 2024-09-01 Crinetics Pharmaceuticals Inc Melanocortin subtype-2 receptor antagonists and uses thereof
WO2021091788A1 (en) 2019-11-07 2021-05-14 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof
EP4556067A3 (en) 2019-12-18 2025-07-30 Crinetics Pharmaceuticals, Inc. Gem-disubstituted piperidine melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof
ES3032933T3 (en) 2019-12-23 2025-07-29 Crinetics Pharmaceuticals Inc Spirocyclic piperidine melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof
KR20220125326A (ko) 2020-01-09 2022-09-14 디스크 메디슨, 인크. 적혈구형성 프로토포르피린증, x-연계된 프로토포르피린증, 또는 선천성 적혈구 조혈포르피린증을 글리신 운반 억제제로 치료하는 방법
CA3195702A1 (en) 2020-10-13 2022-04-21 Boehringer Ingelheim International Gmbh Process of reworking
AU2022240609A1 (en) 2021-03-19 2023-09-28 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (mc2r) antagonist for the treatment of disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5018112A (en) * 1982-10-18 1991-05-21 Conoco Inc. Method for hydrocarbon reservoir identification
IT1176613B (it) * 1984-08-14 1987-08-18 Ravizza Spa Derivati piperazinici farmacologicamente attivi e processo per la loro preparazione
JPH0651625B2 (ja) * 1986-12-29 1994-07-06 株式会社大塚製薬工場 高脂質血症治療剤
PL342818A1 (en) * 1998-03-06 2001-07-02 Janssen Pharmaceutica Nv Glycin transport inhibitors
GB0021419D0 (en) * 2000-08-31 2000-10-18 Oxford Glycosciences Uk Ltd Compounds
DE10112040A1 (de) 2001-03-14 2002-10-02 Aventis Pharma Gmbh Verbessertes Verfahren zur Herstellung von Sulfonylcarboxamidderivaten
EA007468B1 (ru) * 2001-12-20 2006-10-27 Оси Фармасьютикалз, Инк. Пиримидиновые соединения, относящиеся к a-селективным антагонистам, их синтез и применение
AU2004263306B2 (en) 2003-08-11 2010-04-22 F. Hoffmann-La Roche Ag Piperazine with or-substituted phenyl group and their use as GLYT1 inhibitors

Also Published As

Publication number Publication date
MEP27708A (en) 2010-06-10
TNSN06042A1 (en) 2007-10-03
KR100774622B1 (ko) 2007-11-08
JP4252598B2 (ja) 2009-04-08
ME00116B (me) 2010-10-10
US7319099B2 (en) 2008-01-15
CY1108616T1 (el) 2014-04-09
BRPI0413497B1 (pt) 2017-12-19
MY145356A (en) 2012-01-31
EA200600336A1 (ru) 2006-08-25
AR045360A1 (es) 2005-10-26
ZA200601146B (en) 2007-05-30
DK1656361T3 (da) 2008-05-05
EP1656361A1 (en) 2006-05-17
US20080119486A1 (en) 2008-05-22
EA009986B1 (ru) 2008-04-28
SI1656361T1 (sl) 2008-04-30
IL173274A (en) 2012-06-28
DE602004011076T2 (de) 2009-01-02
PT1656361E (pt) 2008-03-05
KR20060037434A (ko) 2006-05-03
US7605163B2 (en) 2009-10-20
AU2004263306A1 (en) 2005-02-17
ATE382611T1 (de) 2008-01-15
ES2297458T3 (es) 2008-05-01
TWI289556B (en) 2007-11-11
JP2007501820A (ja) 2007-02-01
CN1867554A (zh) 2006-11-22
MXPA06001665A (es) 2006-04-28
EG26404A (en) 2013-10-21
RS53252B (sr) 2014-08-29
TW200524883A (en) 2005-08-01
NZ544820A (en) 2009-02-28
CA2534675C (en) 2013-07-23
DE602004011076D1 (de) 2008-02-14
NO332263B1 (no) 2012-08-13
HK1098147A1 (en) 2007-07-13
HRP20080137T3 (en) 2008-06-30
ECSP066358A (es) 2006-08-30
AU2004263306B2 (en) 2010-04-22
MA27995A1 (fr) 2006-07-03
CO5650253A2 (es) 2006-06-30
AU2004263306A2 (en) 2005-02-17
BRPI0413497B8 (pt) 2021-05-25
US20050209241A1 (en) 2005-09-22
PL1656361T3 (pl) 2008-06-30
RS20060076A (sr) 2008-08-07
WO2005014563A1 (en) 2005-02-17
NO20060541L (no) 2006-03-08
IL173274A0 (en) 2006-06-11
BRPI0413497A (pt) 2006-10-17
CN1867554B (zh) 2011-07-06
CA2534675A1 (en) 2005-02-17
EP1656361B1 (en) 2008-01-02
UA85194C2 (ru) 2009-01-12

Similar Documents

Publication Publication Date Title
CR8193A (es) Piperazina con o sustituida de grupos feniles y su uso como inhibidores de glyt 1
BR0313330A (pt) Piperidina-ftalazonas substituìdas com pirrolidinadiona como inibidores de pde4
CR9113A (es) Compuestos acetamida como fungicidas
CR8986A (es) Isoxazoles sustituidos como fungicidas
ECSP10010334A (es) Derivados de quinolina y su uso como fungicidas
BRPI0608886B8 (pt) derivados de n-sulfonilpirróis e seus usos
ECSP12006640A (es) Inhibidores heterocíclicos de aspartil proteasa
NO20071127L (no) Triazoloftalaziner
AR057325A1 (es) Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
CY1109911T1 (el) Πυρρολοβενζοδιαζεπινες
CR10662A (es) Compuestos de metilpiridopirimidinona
SV2001000004A (es) Difenil ureas w-carboxyaril sustituidas, composición farmacéutica que las comprende y su uso como inhibidores de raf quinasa
CL2007001391A1 (es) Compuestos derivados de pirrolidinas sustituidas, inhibidores del factor xa y/o inhibidores sobre la serina proteasa; composicion farmaceutica que comprende a dichos compuestos; proedimiento para preparar la composicon farmaceutica; y uso de los compuestos preparar un medicamneto con un efecto antitrombotico
EA200300836A1 (ru) Производные фталазинон-пиперидина в качестве ингибиторов pde4
CR7977A (es) Anilidas de acido trifluorometil-tiofencarboxilico y su uso como fungicidas
SV2008002906A (es) Metodos y composiciones para modular la hemostasiaref. cho.0267b-sv
CR8451A (es) Uso de derivados de n-arilhidracina para combatir pestes
UY28694A1 (es) Nuevos compuestos
UY30087A1 (es) Piperazinas y piperidinas como potenciadoras de mglur5
CR8177A (es) Compuestos de 3- arilpiridina arilcondensados y su empleo para combatir hongos nocivos
BRPI0408117A (pt) compostos heterocìclicos bifuncionais e métodos de produção e uso dos mesmos
SE9903290D0 (sv) Novel compounds
EA200801365A1 (ru) Замещенные 5-фенил-3,6-дигидро-2-оксо-6h-1,3,4-тиадиазины
EA200801366A1 (ru) Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина
GB0307268D0 (en) Organic compounds